Something went wrong. Please try again later...
JOHNSTON, Iowa -- Enlist E3® soybean varieties have become a trusted trait technology for U.S. farmers -- driving the Enlist® weed control system to become the industry’s fastest-growing soybean herbicide system.
The availability of the first-ever varieties of Pioneer® brand A-Series Enlist E3 soybeans in 2022 helped to bolster farmer adoption of this important herbicide trait technology. These highly anticipated varieties, exclusive to Pioneer, combine the world-class genetics of Pioneer brand A-Series soybeans, the company’s highest-yielding varieties ever, with Enlist® technology, among the most advanced new trait technologies in soybeans.
Don Gehrls, Pioneer Soybean Marketing Lead, says farmers have been asking for a performance boost in Enlist E3 soybeans for years. In 2021, A-Series soybeans delivered a 3 bushels-per-acre yield advantage against all competitors.1
“With fresh challenges every season, farmers need the most consistent performance available,” Gehrls said. “That doesn’t just mean racehorse yields, but also better agronomic performance in key areas like standability and defensive traits to help protect yield from soybean diseases such as white mold and sudden death syndrome.”
Jason Garvick is a Pioneer sales representative with D&J Seeds in Kiester, Minnesota. Several of his customers were able to plant varieties of Pioneer brand A-Series Enlist E3 soybeans this season.
“Farmers were surprised at how quickly Pioneer was able to get exclusive genetics with Enlist E3 soybeans,” Garvick said. “For many farmers that was their biggest hesitation to making the switch, and we’re already seeing a very fast transition. Now, with proven A-Series genetics available in Enlist E3 soybeans — with better disease tolerance and increased yield stability — there’s even more excitement for harvest this season and for more availability next season.”
In all, 28 varieties of A-Series Enlist E3 soybeans were available in limited quantities this season, across a range of maturities. Larger-scale availability is expected across even more maturities to meet farmer demand for 2023 planting.
“We’re seeing a rapid adoption of Enlist E3 soybeans, and farmer interest in 2022 has really exceeded our expectations,” Gehrls said. “With wider availability of A-Series Enlist E3 soybeans next season and the recent re-registration of Enlist herbicides, we’re confident that trend will continue.”
Earlier this year, the EPA granted amended registrations for Enlist One® and Enlist Duo® herbicides for seven years through Jan. 11, 2029, giving farmers certainty in system availability for the foreseeable future.
Learn more at Pioneer.com/US or Enlist.com/FreedomtoSpray.
Pioneer, the flagship seed brand of Corteva Agriscience, is the world’s leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere.
Join the discussion and follow Pioneer on Facebook, Twitter, Instagram and YouTube
Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that combines industry-leading innovations, high-touch customer engagement and operational execution to profitably deliver solutions for the world’s most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.
Follow Corteva on Facebook, Instagram, LinkedIn, Twitter, and YouTube.
# # #
Media Contact:
Larissa Capriotti
+55 (11) 9 9358-4006
larissa.capriotti@corteva.com
1Data based on average of on-farm and IMPACT™ trial comparisons in U.S. in 2021 of the top 25 demand planned A-Series varieties for 2023. Comparisons are against all competitors, unless otherwise stated, and within +/- 0.3 RM of the competitive brand. Product responses are variable and subject to any number of environmental, disease and pest pressures. Individual results may vary. Multi-year and multi-location data are a better predictor of future performance. DO NOT USE THIS OR ANY OTHER DATA FROM A LIMITED NUMBER OF TRIALS AS A SIGNIFICANT FACTOR IN PRODUCT SELECTION. Refer to www.pioneer.com/products or contact a Pioneer sales representative or authorized dealer for the latest and complete listing of traits and scores for each Pioneer® brand product.
The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Corteva Agriscience and M.S. Technologies L.L.C. Enlist Duo® and Enlist One® herbicides are not registered for sale or use in all states or counties. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your area. Enlist Duo and Enlist One are the only 2,4-D products authorized for use with Enlist crops. Consult Enlist herbicide labels for weed species controlled. Always read and follow label directions.
Pioneer® brand products are provided subject to the terms and conditions of purchase which are part of the labeling and purchase documents.
Cautionary Statement About Forward-Looking Statements
This communication contains forward-looking statements and other estimates within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements and other estimates contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “guidance”, “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as expected benefits from, the separation of Corteva from DowDuPont, are forward-looking statements.
Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (xi) impact of Corteva’s dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxii) risks related to COVID-19; (xxiii) risks related to activist stockholders; (xxiv) Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements; (xxvii) other risks related to the Separation from DowDuPont; (xxvii) risks related to the Biden executive order Promoting Competition in the American Economy; and (xxix) risks associated with our CEO transition. Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.